De Novo device
BioTraceIO Lite
Techsomed Medical Technologies , Ltd. · Post-Ablation Tissue Response Prediction Software (QZL, Class II) · First FDA decision Dec 22, 2023, newest Dec 22, 2023Liver disease and liver cancerTumor ablation
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
1
Naming "BioTraceIO Lite"
MAUDE reports
0
Brand "BioTraceIO Lite", since 2015
PubMed studies
0
Mentioning "BioTraceIO Lite"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing BioTraceIO Lite
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- BioTraceIO LiteNew device typeDe Novo
DEN230020 · Decided Dec 22, 2023 · 267 days after receipt
Device type: Post-Ablation Tissue Response Prediction Software (QZL) · Radiology & Imaging
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "BioTraceIO Lite", any status and sponsor, newest update first.
- Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation ProceduresPivotal-lookingCompleted
Techsomed Medical Technologies LTDNot on our public-company list
NCT04970212 · 65 participants · Start Sep 24, 2021 · Primary completion Oct 8, 2022
Device: BioTraceIO Lite · For: Carcinoma, Hepatocellular; Metastatic Liver Cancer
Sites: Phoenix, Arizona; Stanford, California; Boston, Massachusetts · 6 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "BioTraceIO Lite", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QZL
1 reports: 0 malfunction, 1 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "BioTraceIO Lite"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code QZL.
- BioTraceIO Precision (2.0)Techsomed Medical Technologies , Ltd. · 510(k) 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.